Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery.

Abstract

Poly(styrene)-b-poly(DL-lactide) (PS-PDLLA) copolymer-based nanoparticles (NPs) of a narrow size distribution, negative zeta potential, and spherical shape were fabricated for the delivery of docetaxel (DCT). The particle size was consistently maintained in serum for 24 hours and a sustained drug release pattern was observed for 10 days in the tested formulations. The cytotoxicity of the developed blank NPs was negligible in prostate cancer (PC-3) cells. Cellular uptake and distribution of the constructed NPs containing a hydrophobic fluorescent dye was monitored by confocal laser scanning microscopy (CLSM) for 24 hours. Anti-tumor efficacy of the PS-PDLLA/DCT NPs in PC-3 cells was significantly more potent than that of the group treated with commercially available DCT, Taxotere (P<0.05). Blood biochemistry tests showed that no serious toxicity was observed with the blank NPs in the liver and kidney. In a pharmacokinetic study of DCT in rats, in vivo clearance of PS-PDLLA/DCT NPs decreased while the half-life in blood increased compared to the Taxotere-treated group (P<0.05). The PS-PDLLA NPs are expected to be a biocompatible and efficient nano-delivery system for anticancer drugs.

• Authors: Jae-Young Lee, Jung Sun Kim, Hyun-Jong Cho, Dae-Duk Kim
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 9 Pg. 2803-13 ( 2014) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 24940058 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Nanocapsules
• Polyesters
• Polystyrenes
• Taxoids
• Docetaxel
• poly(lactide)

Topics

• Animals
• Antineoplastic Agents (administration & dosage, chemistry, toxicity)
• Cell Line, Tumor
• Cell Survival (drug effects)
• Diffusion
• Docetaxel
• Humans
• Male
• Nanocapsules (administration & dosage, chemistry, toxicity)
• Particle Size
• Polyesters (chemistry, toxicity)
• Polystyrenes (chemistry, toxicity)
• Prostatic Neoplasms (drug therapy, metabolism, pathology)
• Rats
• Rats, Sprague-Dawley
• Taxoids (administration & dosage, pharmacokinetics, toxicity)
• Treatment Outcome